Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TPH1 | P17752 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827292 | 1.00 | TRPM8 (0.38) | TRPM8KMT2ANFE2L2NPC1RAB9A | |
| SCHEMBL2822310 | 0.89 | MAPK1 (0.45) | KMT2ANFE2L2ALDH1A1MEN1MAPT | |
| SCHEMBL2822307 | 0.89 | MAPK1 (0.45) | KMT2ANFE2L2ALDH1A1MEN1MAPT | |
| SCHEMBL2828237 | 0.89 | PDE4A (0.33) | ALDH1A1KDM4EPOLBPDE4BPDE4A | |
| SCHEMBL2828239 | 0.89 | PDE4A (0.33) | ALDH1A1KDM4EPOLBPDE4BPDE4A | |
| SCHEMBL13345648 | 0.86 | TRPM8 (0.36) | TRPM8KMT2ANFE2L2NPC1RAB9A | |
| SCHEMBL2826388 | 0.85 | ACMSD (0.39) | TRPM8KMT2ANFE2L2NPC1RAB9A | |
| SCHEMBL2826386 | 0.85 | ACMSD (0.39) | TRPM8KMT2ANFE2L2NPC1RAB9A | |
| SCHEMBL13287316 | 0.83 | KMT2A (0.43) | TRPM8KMT2ANFE2L2NPC1RAB9A | |
| SCHEMBL2822412 | 0.82 | P2RX3 (0.38) | KMT2AALDH1A1MEN1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| WO-2010070452-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | TRPM8 13/4885KMT2A 3343/4885NFE2L2 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.